Pictet Asset Management (Switzerland)’s Pacira BioSciences PCRX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,979	Closed	-$203K	–	2006
2023 Q1	$203K	Buy	+4,979	New	+$198K	﹤0.01%	1729
2022 Q2	–	Sell	-67,470	Closed	-$5.15M	–	1664
2022 Q1	$5.15M	Sell	67,470 -703	-1%	-$46.9K	0.01%	804
2021 Q4	$4.1M	Sell	68,173 -7,977	-10%	-$440K	﹤0.01%	876
2021 Q3	$4.26M	Buy	+76,150	New	+$4.39M	﹤0.01%	868

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s PCRX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 4,979 shares — an estimated $203K sold.

Pictet Asset Management (Switzerland) first reported a position in PCRX in Q3 2021 and held it in 4 quarters. The position peaked at $5.15M in Q1 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Pictet Asset Management (Switzerland) reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 4,979 Pacira BioSciences shares in Q2 2023, an estimated $203K.
Pictet Asset Management (Switzerland) first reported a position in Pacira BioSciences in Q3 2021 and held it in 4 quarters.
Pictet Asset Management (Switzerland)'s Pacira BioSciences position peaked at $5.15M in Q1 2022.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.